跳至主要内容
临床试验/NL-OMON55366
NL-OMON55366招募中不适用

Assessing the cost-effectiveness of withdrawing growth hormone treatment after mid-puberty in adolescents with idiopathic isolated growth hormone deficiency - Withdrawing growth hormone treatment after mid-puberty

Erasmus MC0 个研究点目标入组 128 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Erasmus MC
入组人数
128

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
12 至 17(—)

入选标准

  • GH treated adolescents with partial idiopathic isolated GH deficiency (IIGHD)
  • GH peak at diagnosis >5 mU/L and <30 mU/L
  • mid-puberty (boys: Tanner stage G3 or G4, testicular volume > 12 ml and bone
  • age 13-16 years; girls: Tanner stage B3 or B4 and bone age 11-14 years)
  • GH peak of > 20 mU/L at retesting in mid-puberty
  • GH treatment for at least 3 years
  • Informed consent

排除标准

  • Medical or psychologic disorder, or medication other than GH, that could
  • potentially influence growth

研究者

发起方
Erasmus MC

相似试验